Evidence map›Paper›PMID 40369458›Full record

ArticleBMC public health2025

The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021.

Wei-Zhen Tang, Qin-Yu Cai, Kang-Jin Huang, Wei-Ze Xu, Jia-Zheng Li, Yun-Ren Pan, Hong-Yu Xu, Yi-Fan Zhao, Ting-He Sheng, Zhi-Mou Li and 2 more

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Ethnomedicinal validation ofFrontiers in nutrition · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wei-Zhen TangDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.ORCID https://orcid.org/0009-0002-8130-7516
Qin-Yu CaiDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Kang-Jin HuangDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Wei-Ze XuDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Jia-Zheng LiDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Yun-Ren PanDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Hong-Yu XuDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Yi-Fan ZhaoDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Ting-He ShengInstitute of Neuroscience, Department of Physiology, School of Basic Medical Science, Chongqing Medical University, Chongqing, 400016, China.
Zhi-Mou LiDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China.
Tai-Hang LiuDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China. liuth@cqmu.edu.cn.ORCID https://orcid.org/0000-0001-9932-8281
Ying-Bo LiDepartment of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, China. liyingbo@cqmu.edu.cn.

Funding

the Natural Science Foundation of Chongqing No. CSTB2024NSCQ-MSX0706
6 · The paper itself

Abstract

backgroundGlobally, common gynecological disorders such as Polycystic Ovary Syndrome (PCOS), endometriosis, uterine fibroids (non-malignant gynecological diseases), as well as cervical cancer, uterine cancer, and ovarian cancer (gynecological cancers), profoundly impact women's physical and mental health. The burden of these diseases exhibits significant geographical disparities across different countries and regions, making a comprehensive and precise assessment of the global burden of gynecological diseases particularly crucial. Such an assessment will facilitate the development of region-specific prevention and treatment strategies, contributing to a more effective response to these health challenges.

methodsIncidence, prevalence, mortality rates, and Disability-Adjusted Life Years (DALYs) data for the aforementioned gynecological conditions were obtained from the 2021 Global Burden of Disease (GBD) study and analyzed by age, location, and year. The burden associated with gynecological diseases was analyzed based on the Socio-demographic Index (SDI) and attributable risk factors. The Estimated Annual Percentage Change (EAPC) and its 95% Confidence Interval (CI) were used to assess temporal trends in burden.

resultsIn 2021, uterine fibroids were the leading non-malignant gynecological condition contributing to the highest Age-Standardized Incidence Rate (ASIR) and Age-Standardized Prevalence Rate (ASPR), with rates of 250.93 and 2841.07 per 100,000, respectively. Cervical cancer was the main contributor to the Age-Standardized Mortality Rate (ASMR) and Age-Standardized Disability Rate (ASDR) among the eight selected gynecological diseases, with rates of 6.62 and 226.28 per 100,000, respectively. From 1990 to 2021, the ASIR and ASPR for non-malignant gynecological conditions, such as PCOS and uterine fibroids, increased, while the ASDR for PCOS also rose. Among gynecological cancers, the ASIR for uterine cancer increased, while the ASPR for cervical cancer rose. However, the ASIR for cervical and ovarian cancers decreased, along with reductions in the ASMR and ASDR for these cancers and uterine cancer. There were notable regional disparities based on the SDI. In 2021, lower SDI regions had higher incidence, prevalence, mortality rates, and DALYs for endometriosis and cervical cancer, whereas higher SDI regions saw higher rates for PCOS, uterine fibroids, ovarian cancer, and uterine cancer, with more significant mortality and DALYs for ovarian and uterine cancers. The age distribution of these conditions varied. Non-malignant gynecological conditions, such as PCOS and uterine fibroids, primarily affect women aged 30-34 and 40-69. Endometriosis is most common in women aged 20-34, particularly between 25 and 29. Gynecological cancers, including cervical, uterine, and ovarian cancers, predominantly affect women over 35, especially between 40 and 69, with cervical cancer peaking at ages 50-54. Regarding attributable risk factors globally, 1% of cervical cancer deaths were linked to unsafe sexual behaviors, while a high Body Mass Index(BMI) contributed to 0.09% of ovarian cancer deaths and 0.34% of uterine cancer deaths.

conclusionThe global burden of these six gynecological conditions poses a significant public health challenge. There is an urgent need for international collaboration to advance the development of age and regionally differentiated management strategies for gynecological diseases, including the development of effective diagnostic screening tools and the implementation of high-quality, targeted prevention and treatment strategies.

Indexed as

EndometriosisGlobal Burden of DiseaseGlobal HealthLeiomyomaOvarian NeoplasmsPolycystic Ovary SyndromeUterine Cervical NeoplasmsUterine NeoplasmsAdolescentAdultAgedDisability-Adjusted Life YearsFemaleHumansIncidenceMiddle AgedBurden of diseaseCervical cancerDisability-adjusted life-years (DALYs)EndometriosisOvarian cancerPolycystic ovary syndromeUterine cancerUterine fibroids

Identifiers

PMID40369458
PMCPMC12077057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.